

# X-LINKED ADRENOLEUKODYSTROPHY IN SOUTH OF TUNISIA

S. Kmiha<sup>1,2</sup>, N. Bouzidi<sup>1</sup>, R. Khalfallah<sup>3</sup>, I. Maaloul<sup>1</sup>, I. Chabchoub<sup>1</sup>, H. Aloulou<sup>1</sup>, H. Kammoun<sup>3</sup>, Th Kammoun<sup>1</sup>.

<sup>1</sup> Pediatrics Department, Hedi Chaker University Hospital, Sfax, Tunisia;

<sup>2</sup> Faculty of Medicine of Sfax, Sfax University, Sfax, Tunisia;

<sup>3</sup> Genetic Department, Hedi Chaker University Hospital, Sfax, Tunisia

## INTRODUCTION

Adrenoleukodystrophy (ALD) is a rare X-linked disease caused by a mutation of the peroxisomal ABCD1 gene. It is a progressive condition with a variable clinical spectrum that includes primary adrenal insufficiency, axonal demyelination and the accumulation of high levels of very long chain fatty acids (VLCFA) in the plasma and tissues.

## AIM

The aim of this study was to describe the clinical, biological, radiological and genetic features of Adrenoleukodystrophy (ALD) in children.

## METHOD

- We performed a retrospective study of all cases of X-linked ALD who were diagnosed in the pediatrics department of the university hospital of Sfax between 2004 and 2020.
- Specific data related to epidemiology, phenotype and diagnosis of patients with X-linked adrenoleukodystrophy were collected and analysed.

## RESULTS


- Six cases of ALD were included.
- The mean age at first symptoms of ALD was 4 years 3 months old ( Range: 16 days- 8 years old)
- Parental consanguinity was noted in one case and a family history of ALD was reported for 4 children.
- For four patients, X- linked ALD started as primary adrenal insufficiency, manifesting with skin hyperpigmentation and vomiting (**Figure 1**).
- For two patients, neurological signs were the first symptoms of the disease (**Table 1**).

Case	C24/C22 (Normal: 0,5-1)	C26/C22 (Normal: 0,002-0,02)
1	1,28	0,09
2	1,27	0,04
3	1,58	0,09
4	1,59	0,62
5	1,77	0,16

**Table 2:** Biochemical results of showing adrenal insufficiency in children with X-linked adrenoleukodystrophy in our study



**Figure 2:** Brain MRI T2 Flair: increased signal in occipital white substance




**Figure 1:** Distribution of children by reason for consultation

Case	Age	Signs of adrenal insufficiency	Neurological signs
1	8 years old	Skin hyperpigmentation-dehydration-hypoglycemia	-
2	7 years and 2 months old	Skin hyperpigmentation- Deshydration	-
3	5 years old	Skin hyperpigmentation	-
4	11 years old	Skin hyperpigmentation – Deshydration	• Epilepsy at the age of 2 years and 2 months old • Pyramidal syndrom at the age of 5 years old
5	16 days	Deshydration – hypoglycemia	• Delay in psychomotor development • Attention difficulties
6	3 years old	Skin hyperpigmentation	

**Table 1:** Clinical manifestation at onset of X-linked adrenoleukodystrophy in our study

Case	Serum CORTISOL (normal: 20-200ng/ml)	Serum ACTH (normal: 10-48 ng/l)	Serum Renine (normal: 3,5-20 pg/ml)	Aldosterone (pmol/l)
1	13,8	13700	41,7	87
2	4,27	1480	86,9	61
3	53	3882	35,8	171
4	38	>1000	-	58
5	4,4	1722	20	61
6	2	1250	40,5	640

**Table 3:** The plasma very long chain fatty acids (VLCFA) levels at onset of X-linked adrenoleukodystrophy in our study



**Figure 3:** Clinical evolution of children with X-linked adrenoleukodystrophy in our study

- Brain magnetic resonance imaging (MRI) showed signs of leukodystrophy in 2 cases (**Figure 2**).
- The plasma very long chain fatty acids (VLCFA) levels were significantly increased for five children (**Table 2**).
- Genetic testing identified the mutation of ABCD1 gene in 4 cases
- All children developed adrenal insufficiency during the course of the disease (**Table 3**) and 2 children progressed to a cerebral phenotype (**Figure 3**).

## CONCLUSIONS

- X-linked ALD should be screened for boys with adrenal insufficiency.
- This disorder is confirmed by serum VLCFA levels and/or genetic testing.
- Confirmation of the diagnosis of X-ALD by analysis of mutations in ABCD1 is particularly recommended to identify heterozygous women and for antenatal diagnosis of ALD.

## CONTACT INFORMATION

Mail contact: [sanakmiha24@yahoo.fr](mailto:sanakmiha24@yahoo.fr)